Monthly Archives: February 2013




Oxford PV is developing a solid state dye sensitized solar cell which is optimised to drive a paradigm shift in the aesthetics, performance and cost of Building Integrated Photovoltaic (BIPV) systems.


Leave a comment

February 27, 2013 · 8:27 pm

BioVex Amgen

155x70 BioVex logo

Major focus is on the development of novel biologics for cancer and infectious disease. For more than 27 years, Amgen scientists have applied innovative research to advance important new therapies for grievous illnesses. Amgen’s heritage lies in leading-edge molecular biology. This basic science platform permitted the development of protein therapeutics that have transformed the management of anaemia, inflammation, and cancer.

More recently, Amgen has assembled a multidisciplinary group of chemists and biologists who, together, approach the challenge of drug discovery using multiple potential therapeutic modalities. The research program that was started 27 years ago has grown spectacularly, yielding a heightened understanding of human disease, and innovative new approaches to improving human health.

Leave a comment

February 26, 2013 · 9:48 pm

Absynth Biologics

absynth logo 150

Absynth Biologics is focussed on the development of vaccines and antibodies to treat bacterial infection. The company’s distinctive approach uses genomics to identify highly conserved bacterial protein targets, essential for life and capable of stimulating the immune system. Absynth’s  lead programme focuses on infections  caused by the bacterium Staphylococcus aureus (S. aureus) including its more difficult-to-treat drug-resistant form, methicillin-resistant S. aureus (MRSA).



February 26, 2013 · 9:43 pm

Insception Lifebank


Insception Lifebank offers expectant parents a professionally acknowledged quality service. Along with being the first to achieve the AABB accreditation, Insception Lifebank is the first family cord blood bank in Canada to receive the industry’s highest accreditation, FACT.


Leave a comment

February 26, 2013 · 9:32 pm



Tissue Regeneration Therapeutics (TRT) develops our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) technology platform, to provide licensing opportunities to collaborating partners.


Leave a comment

February 26, 2013 · 9:27 pm



Advanced solutions for lab-on-a-chip devices

Kapplex solutions are powered by Digital Microfluidics (DMF) technology which overcome the challenges of conventional channel microfluidics. With the lack of moving parts, valves or tubes, DMF devices are capable of manipulating droplet-sized fluids on simple, low cost platforms with high flexibility and easy multiplexing.

Smart Well PlateTM     High-throughput assays for precious sample analysis

Smart ScreenTM for dried blood analysis     Low-cost on-chip blood sample analysis


1 Comment

February 26, 2013 · 9:19 pm





Xagenic is a molecular diagnostics company developing a true point- of-care platform. Our aim is to enable on-demand, near patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of first consultation. This will dramatically improve patient care and reduce health care costs.


Leave a comment

February 26, 2013 · 9:09 pm





INTERFACE BIOLOGICS, INC. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.

Our primary technology focus areas are anti-thrombogenic additives that reduce thrombosis and programmable combination drug delivery devices.

The company was founded in 2001 based on the work of Dr. Paul Santerre at the University of Toronto. The name, Interface Biologics, comes from the critical interface between the human body and medical devices at the molecular level.



Leave a comment

February 22, 2013 · 6:44 pm

BIOX Corporation


BIOX Corporation is a spin off of University of Toronto specialized in renewable energy and designs, builds, owns and operates a 67 million litre per annum nameplate capacity biodiesel production facility in Hamilton, Ontario Canada. Their innovative production process is significantly faster and achieves higher yields than competing methods while utilizing the widest variety of feedstocks ranging from pure seed oils to animal fats to recovered vegetable oils with no change to our production process. Their high quality biodiesel fuel meets  North American (ASTM) quality standards.

View the financial report



Leave a comment

February 22, 2013 · 6:27 pm


Changing the way fuels are made…

oxford catalysts2

The Oxford Catalysts Group is helping to create a better fuel future through innovation in processing technology

  • Gas-to-Liquids Small scale distributed GTL systems for use on- and off-shore
  • Fischer-Tropsch Fischer-Tropsch microchannel reactors and catalysts for the distributed production of synthetic oil through small scale gas-, biomass-, coal- and waste- to-liquids applications
  • Microchannel process technology Small footprint reactors that enable large scale economics for smaller scale plants
  • Superactive catalysts Oxford Catalysts’ patented OMX method for catalyst production, making catalysts with just the right properties


1 Comment

February 22, 2013 · 3:37 pm

Gene Therapy







Oxford University Science Blog Articles provide information about Gene Therapy and Biotech Start ups.



Leave a comment

February 21, 2013 · 5:42 pm

Therapure Biopharma Inc.


Therapure Biopharma Inc. is an integrated contract development and manufacturing organization (CDMO) that develops and manufactures (upstream and downstream processing) therapeutic proteins as well as provides aseptic fill/finish services for both complex biologics and small molecules.

Therapure Biopharrma Inc. has been awarded the Gold Leaf Award for Emerging Company of the Year by BIOTECanada in the Health Biotech Category for 2012.  Therapure has been recognized as an outstanding emerging health company for the potential of its unique biomanufacturing capabilities as well as its highly innovative drug discovery pipeline.


Leave a comment

February 19, 2013 · 1:16 am




IXO is a biotechnology company researching and developing novel immunotherapeutics targeting the innate immune system. Focusing on the initiators of the adaptive immune response, IXO’s products address significant unmet clinical need in areas of high commercial value. Based in the UK, IXO’s products are in late-stage research and preclinical development based on IP derived from both NERC
and the University of Oxford.


Leave a comment

February 19, 2013 · 12:52 am

Oxford Imaging Detectors


Oxford Imaging Detectors is developing high performance scientific imaging detectors capable of studying structures and processes at the atomic level. Initially focussed for use in electron microscopy, the detectors were developed by the research group lead by Professor Angus Kirkland at the University’s Department of Materials. They provide significant advantages over current technology, exceeding the current state of the art in speed, contrast, efficiency and resolution.


Leave a comment

February 19, 2013 · 12:50 am

Intelligent Ultrasound IU






Intelligent Ultrasound develops software that improves significantly the quality, field of view and diagnostic power of medical ultrasound scans.

The company’s application-specific products are based on a clinically proven and proprietary technology platform that is the subject of multiple peer-review publications.


Leave a comment

February 19, 2013 · 12:42 am


logo ox





Oxehealth, spun out from Oxford’s Institute of Biomedical Engineering, will allow patient’s health to be monitored using a webcam and a software application.

The software will detect a patient’s heart rate, respiratory rate and oxygen saturation even in artificial light without the need for any physical contact or additional hardware.


Leave a comment

February 19, 2013 · 12:34 am


A spin-out from the University of Oxford, Oxford Vacmedix, will commercialise a new technology with the potential to reduce the cost of vaccine development significantly and increase the effectiveness of vaccines in providing immunity against both infectious diseases and cancer.  The technology makes use of techniques that have already produced effective vaccines under laboratory conditions.


Leave a comment

February 19, 2013 · 12:31 am

Hyperion HPTX



Hyperion Therapeutics’ RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders

  • Anticipated market launch by end of April 2013
  • Patent allowance extends coverage to 2032

Feb. 1, 2013: Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the U.S. Food and Drug Administration (FDA) has approved RAVICTI for the treatment of Urea Cycle Disorders (UCD) in patients two years of age and older. The drug is expected to be commercially available by the end of April 2013.


Leave a comment

February 19, 2013 · 12:28 am



XOMA Corporation (XOMA): XOMAs extensive antibody expertise includes antibody discovery, optimization, cell line and process development and manufacture of therapeutic antibodies to treat inflammatory, autoimmune, infectious, and oncological diseases.


Leave a comment

February 19, 2013 · 12:15 am

Oxygen Biotherapeutics OXBT

logo_oxybioDevelops medical and cosmetic products that deliver oxygen to tissues in the body.

Oxygen Biotherapeutics is the tissue oxygenation company.

Oxygen Biotherapeutics and the U.S. Army Institute of Surgical Research Sign a Cooperative Research and Development Agreement to Study the Effects of Oxycyte® on Ex Vivo Platelet Function.

Wounds, Traumatic Brain Injury, Dermatology


Leave a comment

February 19, 2013 · 12:05 am

BioSpecifics BSTC




BioSpecifics Technologies Corp. (BSTC):

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Injectable collagenase is marketed as XIAFLEX® in the United States for the treatment of adult Dupuytren’s contracture patients with a palpable cord in the palm by BioSpecifics’ strategic partner Auxilium Pharmaceuticals, Inc. and is approved for Dupuytren’s contracture in the European Union and Canada.


Leave a comment

February 18, 2013 · 11:56 pm


dendrionInVisage has built the world’s most sensitive mobile camera: every photon incident is immediately absorbed, and its electronic signal is routed to the right pixel. This translates into clear images in any lighting condition, and sharpness of detail and color.

InVisage has enabled a new concept in zoom, Dynamic Zoom, that allows them to scale resolution on–the–fly.

Leave a comment

February 18, 2013 · 11:40 pm

TrovaGene TROV


TrovaGene (TROV)


Trovagene, Inc. is a publicly traded molecular diagnostics company with headquarters in San Diego, California.  It has fundamental intellectual property around the remarkable discovery that cell-free DNA, RNA and other types of nucleic acids pass through the kidney into the urine.  These “Transrenal Nucleic Acids”, or “TrNAs”, can be diagnostic of diseases such as cancer and infection.



Leave a comment

February 18, 2013 · 11:33 pm



Nexeon has patented a unique way of structuring silicon so that it delivers extended cycle life and significantly increases battery capacity.

In contrast to carbon, Nexeon’s silicon anode materials have a much higher capacity for lithium and as a result are capable of almost ten times the energy capacity per gram (mAh/g).


Leave a comment

February 18, 2013 · 10:53 pm

Oncolytics Biotech Inc.

Oncolytics Biotech Inc. (ONCY): Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers.


Leave a comment

February 18, 2013 · 10:49 pm

Population Diagnostics




Population Diagnostics discovers causative genetic biomarkers to:

  • Develop and market DNA-based diagnostic tests for pre-symptomatic early detection of disease.
  • Enable pharmaceutical companies to develop companion diagnostics and novel targeted drugs with greater efficacy and safety.

Outlicensing Opportunities

Population Diagnostics has intellectual property portfolios in Parkinson’s disease and Autism Spectrum Disorder comprising causative biomarker collections for both therapeutic and diagnostics applications. In addition to active discovery programs in a variety of diseases (see figure), our technology highly enables the cytogenetics diagnostic market. Population Diagnostics pursues alliances with microarray providers serving the cytogenetics community.


Leave a comment

February 18, 2013 · 10:23 pm




We use advanced motion analysis to help understand the root-cause of your injury and provide long-term results


Leave a comment

February 18, 2013 · 10:15 pm

Oxford Medical Diagnostics OMD


Oxford Medical Diagnostics develops and supplies breath analysis technologies for rapid, accurate, and low-cost monitoring of diseases and metabolic functions.


Leave a comment

February 18, 2013 · 10:08 pm

Oxford Gene Technology OGT




Oxford Gene Technology (OGT)

CytoSure Haematological Cancer +SNP Array

Reliable detection of copy number changes and loss of heterozygosity on a single array for the haematological malignancies Chronic Lymphocytic Leukaemian CLL, Multiple Myeloma MM, Myeloproliferative Neoplasms MPN and Myelodysplastic Syndromes MDS.


Leave a comment

February 18, 2013 · 10:02 pm

Oxford Advanced Surfaces OXA





Optical Properties of VISARC™ Films

An anti-reflective coating (ARC) is a thin film of material that is processed on to a substrate in order to significantly reduce its visible light reflection. Typical glass and polymer substrates reflect a fair proportion of the light falling directly on them (approximately 4.5-6% per side), with the reflectance increasing as the viewing angle increases. This occurs at both surfaces so in total at least 9-10% of sunlight is reflected from the substrate.

Onto™ Just About Anything

The highly reactive nature of Onto™ means that it is compatible with a diverse range of materials, so it can be used to modify almost any type of surface, including:

  • Synthetic polymers such as polyolefins, polyacrylates, polyesters, polyamides, polyimides, polycarbonates, polyaramids, polystyryls, polysulfones, fluoropolymers and rubbers
  • Natural polymers such as cotton and wool
  • Inorganic Surfaces such as glasses, alumina, silicon, diamond, graphite and carbon fibre
  • Metal surfaces such as steel, aluminium and copper

Leave a comment

February 18, 2013 · 9:49 pm



uBiome is the world’s first effort to map the human microbiome with citizen science.

While the sequencing of the human genome has provided invaluable knowledge, it is very difficult to change our own genetic makeup. The microbiome, in contrast, is much more easily changed through simple means such as healthful probiotic cultures and other lifestyle interventions.


Leave a comment

February 18, 2013 · 9:38 pm

OrganOx Ltd




OrganOx Ltd:  OrganOx® Limited is a late-stage medical device development company that was founded in April 2008 as a spin-out from the University of Oxford.

The OrganOx metra, will be commercially available in 2013 and will enable the repair, preservation and objective viability assessment of livers prior to transplantation for up to 24 hours using normothermic oxygenated blood. Through the use of the metra we aim to increase the number of livers available for transplant.

The metra utilises a patented process of “auto-regulation” allowing the liver to self-regulate pressures and flows of oxygenated blood at normothermic temperatures. The auto-regulation method and algorithms have been developed through over 15 years of research with over 200 pre-clinical perfusions reported in over 30 peer-reviewed publications and reviews.


Leave a comment

February 18, 2013 · 9:31 pm

OrganOvo ONVO



Organovo Holdings, Inc. (ONVO.PK) has seen tremendous growth in the early trading days of the year. After hitting an intra-week high of $3.99 ONVO reversed slightly and now appears to have settled around 3.20, up nearly 36 percent from the start of the New Year.

The San Diego based company designs and develops functional human tissues using their own proprietary three-dimensional bio-printing technology. ONVO is the developer of the NovoGen MMX Bioprinter™, the world’s only commercial Bioprinter proven to create tissue. Their proprietary technology employs a specified automated platform that works across all tissue and cell types. They are the first company in the world to possess such technology and in recognition; Organovo’s bio-printer was named one of the “Best Inventions of 2010” by TIME Magazine.


Leave a comment

February 18, 2013 · 9:16 pm

Oxford Pharmascience OXP


OXP Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx and OTC branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API.

Oxford Pharmascience (LON:OXP) has successfully completed the formulation development for its Safestat formulations of Atorvastatin and Simvastatin, the leading generic statin drugs.

The company has proven in-vitro release under simulated human conditions.


Leave a comment

February 18, 2013 · 8:36 pm

Oxford Cancer Biomarkers OCB


Personalising cancer medicines

Our pioneering biomarker technology predicts which cancer patients will respond favourably to existing and emerging cancer drugs, allowing treatment to be tailored to individual patients.

Assisting partner companies to achieve rapid market entry

We are looking to partner with leading care organisations and drug development companies.


Leave a comment

February 18, 2013 · 8:25 pm




The OXEMS Solution has three fully integrated elements: OXEMS Tags + OXEMS Detector + OXEMS Database. These three combine to deliver the most economical, accurate and intelligent underground asset registration, mapping and management system available – the OXEMS Fully Integrated Solution.

An overview of the OXEMS system for precise surface identification and location of underground assets.

Watch Introduction Animation


Leave a comment

February 18, 2013 · 8:20 pm



Addressing Dopamine Deficiency in Parkinson’s Disease



Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at and



Leave a comment

February 18, 2013 · 8:12 pm

EIS Electrochemical Impedance Spectroscopy






Electrochemical Impedance Spectroscopy EIS has the ability to elucidate range of physical and electronic properties of electrochemical systems such as diffusion coefficients, electron transfer rate constants, adsorption mechanisms, charge transfer resistances, capacitances and pore sizes. Find a short introduction to the fundamental principles of EIS and many exciting and pertinent analytical applications regarding the numerous methods in biosensing, the application of EIS with graphene based materials and the use of EIS with screen printed electrodes –Banks et al, Click here:


Leave a comment

February 15, 2013 · 5:54 pm

OUP Winter Book Sale Upto 75% Off


Please note that these offers only apply to individual customers when ordering direct from Oxford University Press, while stocks last. No further discounts will apply. Offer ends Thursday 28th Februrary, 2013.


Leave a comment

February 13, 2013 · 2:35 pm

Imaging Predictions of Toxicity



Applications of High Content Analysis in Pharmaceutical and Consumer Products Safety Testing

High content analysis (HCA) has emerged as an important technology for in vitro toxicity testing. Using automated microscopy, image analysis, and primary or immortalized cells, HCA offers superior performance to animal testing at a fraction of the expense. This technology is applied to screening for drug/chemical induced liver injury, reproductive toxicity, genetic toxicity, neurotoxicity and immunotoxicity. This seminar will define the technology, detail the validation of several assays and present case.

Leave a comment

February 13, 2013 · 2:21 pm

Oxford University Press Book Sale Upto % 75 Off






Please note, this offer price only applies to individual customers when ordering direct from Oxford University Press, while stock lasts. No further discounts will apply. If you are a bookseller, please contact your OUP sales representative.

roger penrose


Roger Penrose: Collected Works

Volume 2: 1968-1975

Roger Penrose
960 pages | 246x189mm
978-0-19-921937-7 | Hardback | 14 October 2010

Price: £135.00   Sale Price: £67.50


1 Comment

February 8, 2013 · 4:17 pm